 <h1>Daclatasvir Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Side effects</li>
<li>Professional</li>
<li>FAQ</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to daclatasvir: oral tablet</i></p><h3>
        Warning
      </h3><ul>
<li>You will be tested for hepatitis B before starting this drug. In people who have had hepatitis B or carry the virus, the virus has become
        active again during or after treatment with drugs like this one. This can lead to severe and sometimes deadly liver problems. People with
        hepatitis B and hepatitis C will be watched closely during and after treatment.
        </li>
</ul><h2 class="ddc-anchor-offset" id="side-effects">What are some side effects that I need to call my doctor about right away?</h2><p>
      WARNING/CAUTION: Even though it may be rare, some people may have very bad and sometimes deadly side effects when taking a drug. Tell your
      doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect:
    </p><ul>
<li>Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing;
      tightness in the chest or throat; trouble breathing, swallowing, or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue,
      or throat.
      </li>
<li>Signs of liver problems like dark urine, feeling tired, not hungry, upset stomach or stomach pain, light-colored stools, throwing up, or
      yellow skin or eyes.
      </li>
<li>Signs of low blood sugar like dizziness, headache, feeling sleepy, feeling weak, shaking, a fast heartbeat, confusion, hunger, or sweating.
      </li>
<li>Feeling very tired or weak.
      </li>
<li>Shortness of breath.
      </li>
<li>Dizziness or passing out.
      </li>
<li>Pale skin.
      </li>
</ul><h2>
      What are some other side effects of this drug?
    </h2><p>
      All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor or get medical
      help if any of these side effects or any other side effects bother you or do not go away:
    </p><ul>
<li>Headache.
      </li>
<li>Feeling tired or weak.
      </li>
<li>Upset stomach.
      </li>
<li>Diarrhea.
      </li>
<li>Trouble sleeping.
      </li>
</ul><p>
      These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical
      advice about side effects.
    </p><p>
      You may report side effects to the FDA at 1-800-332-1088. You may also report side effects at https://www.fda.gov/medwatch.
    </p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to daclatasvir: oral tablet</i></p><h3>General</h3><p>In clinical trials, this drug was used in combination with sofosbuvir (with or without ribavirin), with peginterferon alfa/ribavirin, with asunaprevir, or with asunaprevir/peginterferon alfa/ribavirin.  Fatigue, headache, and nausea were reported most often when used with sofosbuvir.  Headache, anemia, fatigue, and nausea were reported most often when used with sofosbuvir and ribavirin.  Fatigue, headache, pruritus, insomnia, influenza-like illness, dry skin, nausea, decreased appetite, alopecia, rash, asthenia, irritability, myalgia, anemia, pyrexia, cough, dyspnea, neutropenia, diarrhea, and arthralgia were reported most often when used with peginterferon alfa/ribavirin; the most common side effects of at least grade 3 severity were neutropenia, anemia, thrombocytopenia, and lymphopenia.  The side effects and laboratory abnormalities reported with this drug in combination with peginterferon alfa/ribavirin was similar to those reported with peginterferon alfa/ribavirin alone, including in patients with cirrhosis.  Headache, fatigue, diarrhea, nasopharyngitis, and nausea were reported most often when used with asunaprevir.  Fatigue, headache, pruritus, asthenia, influenza-like illness, insomnia, rash, anemia, cough, dry skin, diarrhea, nausea, alopecia, irritability, pyrexia, and myalgia were reported most often when used with asunaprevir/peginterferon alfa/ribavirin.</p><p></p><p>The manufacturer product information for coadministered hepatitis C virus (HCV) antiviral drugs should be consulted.<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (up to 41.5%), asthenia (up to 24.1%), influenza-like illness (up to 22.4%), pyrexia (up to 16.1%)</p><p><b>Common</b> (1% to 10%): Hot flush, pain, weight decreased<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (up to 31.2%)</p><p><b>Common</b> (1% to 10%): Dizziness, migraine, somnolence<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Pruritus (up to 26.1%), rash (up to 20.6%), dry skin (up to 17.8%), alopecia (up to 16.1%)</p><p><b>Postmarketing reports</b>: Erythema multiforme<sup>[Ref]</sup></p><p>Erythema multiforme has been reported with this drug as part of an asunaprevir regimen.<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Insomnia (up to 22.4%), irritability (up to 16.1%)</p><p><b>Common</b> (1% to 10%): Depression, anxiety<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Of the patients reporting anemia, 43% received ribavirin in addition to this drug and sofosbuvir.  During the study, anemia was not reported in the ribavirin-free treatment groups.</p><p></p><p>In trials of this drug with sofosbuvir (with or without ribavirin), grade 3 decreased hemoglobin was reported in 2% of patients; all of these patients received this drug with sofosbuvir and ribavirin.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Anemia (up to 20%), neutropenia (up to 14.8%)</p><p><b>Common</b> (1% to 10%): Thrombocytopenia, decreased hemoglobin</p><p><b>Frequency not reported</b>: Eosinophilia<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Cough (up to 18.3%), nasopharyngitis (up to 13.7%), dyspnea (up to 12.3%)</p><p><b>Common</b> (1% to 10%): Exertional dyspnea, nasal congestion, upper respiratory tract infection<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Elevated lipase (at least 3.1 times the upper limit of normal [3.1 x ULN]) was reported in up to 4% of patients using this drug with sofosbuvir (with or without ribavirin).<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Diarrhea (up to 17.6%), nausea (up to 16.6%)</p><p><b>Common</b> (1% to 10%): Upper abdominal pain, abdominal pain, constipation, flatulence, gastroesophageal reflux disease, dry mouth, vomiting, elevated lipase<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Myalgia (up to 15.3%), arthralgia (up to 10.1%)</p><p><b>Common</b> (1% to 10%): Back pain<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Decreased appetite (up to 11.8%)<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>Serious symptomatic bradycardia has been reported in patients taking amiodarone who started therapy with a regimen containing sofosbuvir.  Cases of severe bradycardia and heart block have been reported with this drug in combination with sofosbuvir and concomitant amiodarone and/or other drugs that lower heart rate.<sup>[Ref]</sup></p><p><b>Postmarketing reports</b>: Symptomatic bradycardia, heart block, cardiac arrhythmias<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Increased ALT, increased AST, increased total bilirubin</p><p><b>Postmarketing reports</b>: Hepatitis B reactivation<sup>[Ref]</sup></p><p>Increased ALT (at least 5.1 x ULN), AST (at least 5.1 x ULN), and total bilirubin (at least 2.6 x ULN) were reported in up to 4%, up to 3%, and up to 8% of patients, respectively.</p><p></p><p>Grade 3/4 increased total bilirubin was reported in 5% of patients; all of these patients were coinfected with HIV and using concomitant atazanavir, had Child-Pugh A, B, or C cirrhosis, or were post-liver transplant.<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Urinary tract infection</p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Dry eye<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. "Product Information. Daklinza (daclatasvir)." Bristol-Myers Squibb, Princeton, NJ. </p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>What are the new drugs for the treatment of hepatitis C?</li>
<li>How much does Daklinza cost?</li>
</ul><h2>More about daclatasvir</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>10 Reviews</li>
<li>Drug class: NS5A inhibitors</li>
<li>FDA Alerts (1)</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Advanced Reading</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Hepatitis C</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>